Colistin plasma concentrations are not associated with better clinical outcomes in patients with pneumonia caused by extremely drug-resistant Pseudomonas aeruginosa

In some cases, colistin is the only treatment option for infections caused by the very drug-resistant Pseudomonas aeruginosa. However, in the past decade, there have been questions concerning its pharmacokinetics and concentration at the site of infection. In this scenario, its use in a difficult-to...

Descripción completa

Detalles Bibliográficos
Autores: Sorli Redó, M. Luisa, Luque Pardos, Sònia, Li, Jian, Benítez-Cano, Adela, Fernández, Xenia, Prim, Núria, Vega, Victoria, Gómez Junyent, Joan, López Montesinos, Inmaculada, Gómez-Zorrilla, Silvia, Montero, Maria Milagro, Grau Cerrato, Santiago, Horcajada Gallego, Juan Pablo
Tipo de recurso: artículo
Estado:Versión publicada
Fecha de publicación:2023
País:España
Institución:Universitat Pompeu Fabra
Repositorio:Repositorio Digital de la UPF
OAI Identifier:oai:repositori.upf.edu:10230/68379
Acceso en línea:http://hdl.handle.net/10230/68379
http://dx.doi.org/10.1128/spectrum.02967-23
Access Level:acceso abierto
Palabra clave:Pseudomonas aeruginosa
Colistin
Pharmacokinetics
Pneumonia
id ES_f4b18ee8fcd52291a4bce2bd724c9d9f
oai_identifier_str oai:repositori.upf.edu:10230/68379
network_acronym_str ES
network_name_str España
repository_id_str
spelling Colistin plasma concentrations are not associated with better clinical outcomes in patients with pneumonia caused by extremely drug-resistant Pseudomonas aeruginosaSorli Redó, M. LuisaLuque Pardos, SòniaLi, JianBenítez-Cano, AdelaFernández, XeniaPrim, NúriaVega, VictoriaGómez Junyent, JoanLópez Montesinos, InmaculadaGómez-Zorrilla, SilviaMontero, Maria MilagroGrau Cerrato, SantiagoHorcajada Gallego, Juan PabloPseudomonas aeruginosaColistinPharmacokineticsPneumoniaIn some cases, colistin is the only treatment option for infections caused by the very drug-resistant Pseudomonas aeruginosa. However, in the past decade, there have been questions concerning its pharmacokinetics and concentration at the site of infection. In this scenario, its use in a difficult-to-treat infection like pneumonia is currently debatable. This is a clinical pharmacokinetic study of colistin in patients with multidrug-resistant P. aeruginosa pneumonia. Our findings demonstrate that colistin exposure is associated with worse clinical outcomes rather than better clinical outcomes, implying that other therapeutic options should be explored in this clinical setting.American Society for Microbiology202420242023info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionapplication/pdfapplication/pdfhttp://hdl.handle.net/10230/68379http://dx.doi.org/10.1128/spectrum.02967-23reponame:Repositorio Digital de la UPFinstname:Universitat Pompeu FabraInglésMicrobiol Spectr. 2023 Dec 12;11(6):e0296723© 2023 Sorlí et al. This is an open-access article distributed under the terms of the Creative Commons Attribution 4.0 International license (https://creativecommons.org/licenses/by/4.0/).http://creativecommons.org/licenses/by/4.0/info:eu-repo/semantics/openAccessoai:repositori.upf.edu:10230/683792026-06-12T07:21:37Z
dc.title.none.fl_str_mv Colistin plasma concentrations are not associated with better clinical outcomes in patients with pneumonia caused by extremely drug-resistant Pseudomonas aeruginosa
title Colistin plasma concentrations are not associated with better clinical outcomes in patients with pneumonia caused by extremely drug-resistant Pseudomonas aeruginosa
spellingShingle Colistin plasma concentrations are not associated with better clinical outcomes in patients with pneumonia caused by extremely drug-resistant Pseudomonas aeruginosa
Sorli Redó, M. Luisa
Pseudomonas aeruginosa
Colistin
Pharmacokinetics
Pneumonia
title_short Colistin plasma concentrations are not associated with better clinical outcomes in patients with pneumonia caused by extremely drug-resistant Pseudomonas aeruginosa
title_full Colistin plasma concentrations are not associated with better clinical outcomes in patients with pneumonia caused by extremely drug-resistant Pseudomonas aeruginosa
title_fullStr Colistin plasma concentrations are not associated with better clinical outcomes in patients with pneumonia caused by extremely drug-resistant Pseudomonas aeruginosa
title_full_unstemmed Colistin plasma concentrations are not associated with better clinical outcomes in patients with pneumonia caused by extremely drug-resistant Pseudomonas aeruginosa
title_sort Colistin plasma concentrations are not associated with better clinical outcomes in patients with pneumonia caused by extremely drug-resistant Pseudomonas aeruginosa
dc.creator.none.fl_str_mv Sorli Redó, M. Luisa
Luque Pardos, Sònia
Li, Jian
Benítez-Cano, Adela
Fernández, Xenia
Prim, Núria
Vega, Victoria
Gómez Junyent, Joan
López Montesinos, Inmaculada
Gómez-Zorrilla, Silvia
Montero, Maria Milagro
Grau Cerrato, Santiago
Horcajada Gallego, Juan Pablo
author Sorli Redó, M. Luisa
author_facet Sorli Redó, M. Luisa
Luque Pardos, Sònia
Li, Jian
Benítez-Cano, Adela
Fernández, Xenia
Prim, Núria
Vega, Victoria
Gómez Junyent, Joan
López Montesinos, Inmaculada
Gómez-Zorrilla, Silvia
Montero, Maria Milagro
Grau Cerrato, Santiago
Horcajada Gallego, Juan Pablo
author_role author
author2 Luque Pardos, Sònia
Li, Jian
Benítez-Cano, Adela
Fernández, Xenia
Prim, Núria
Vega, Victoria
Gómez Junyent, Joan
López Montesinos, Inmaculada
Gómez-Zorrilla, Silvia
Montero, Maria Milagro
Grau Cerrato, Santiago
Horcajada Gallego, Juan Pablo
author2_role author
author
author
author
author
author
author
author
author
author
author
author
dc.subject.none.fl_str_mv Pseudomonas aeruginosa
Colistin
Pharmacokinetics
Pneumonia
topic Pseudomonas aeruginosa
Colistin
Pharmacokinetics
Pneumonia
description In some cases, colistin is the only treatment option for infections caused by the very drug-resistant Pseudomonas aeruginosa. However, in the past decade, there have been questions concerning its pharmacokinetics and concentration at the site of infection. In this scenario, its use in a difficult-to-treat infection like pneumonia is currently debatable. This is a clinical pharmacokinetic study of colistin in patients with multidrug-resistant P. aeruginosa pneumonia. Our findings demonstrate that colistin exposure is associated with worse clinical outcomes rather than better clinical outcomes, implying that other therapeutic options should be explored in this clinical setting.
publishDate 2023
dc.date.none.fl_str_mv 2023
2024
2024
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv http://hdl.handle.net/10230/68379
http://dx.doi.org/10.1128/spectrum.02967-23
url http://hdl.handle.net/10230/68379
http://dx.doi.org/10.1128/spectrum.02967-23
dc.language.none.fl_str_mv Inglés
language_invalid_str_mv Inglés
dc.relation.none.fl_str_mv Microbiol Spectr. 2023 Dec 12;11(6):e0296723
dc.rights.none.fl_str_mv http://creativecommons.org/licenses/by/4.0/
info:eu-repo/semantics/openAccess
rights_invalid_str_mv http://creativecommons.org/licenses/by/4.0/
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
application/pdf
dc.publisher.none.fl_str_mv American Society for Microbiology
publisher.none.fl_str_mv American Society for Microbiology
dc.source.none.fl_str_mv reponame:Repositorio Digital de la UPF
instname:Universitat Pompeu Fabra
instname_str Universitat Pompeu Fabra
reponame_str Repositorio Digital de la UPF
collection Repositorio Digital de la UPF
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869424494962016256
score 15.81155

Similares en LA Referencia